Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
|Videos|January 15, 2021
eConsults demonstrate utility in urology
Author(s)Urology Times staff
Researchers evaluated the use of interprofessional consultations within the specialty of urology.
Advertisement
In this interview, Chad Ellimoottil, MD, MS, discusses the recent Urology Practice study, “Interprofessional Consultations (eConsults) in Urology,” for which he served as senior author. Ellimoottil is an assistant professor of urology at the University of Michigan, Ann Arbor.
Advertisement
Related to this article
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Engy Habashy, MD, discusses key takeaways from the 2025 AUA GSM guideline, including the role of androgens and hormonal therapies in managing genitourinary syndrome of menopause.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Advertisement
Advertisement
Trending on Urology Times
1
Adding darolutamide to ADT and radiation improves MFS in very high-risk localized prostate cancer
2
VOLGA: Durvalumab plus enfortumab vedotin improves EFS, OS in MIBC
3
PROTEUS Substudy: Perioperative apalutamide plus ADT improves EFS vs surgery alone
4
In situ immunotherapy shows encouraging survival findings in prostate cancer
5